Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Muvalaplin?
Muvalaplin is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Atherosclerosis. According...
Muvalaplin by Eli Lilly and Co for Atherosclerosis: Likelihood of Approval
Muvalaplin is under clinical development by Eli Lilly and Co and currently in Phase II for Atherosclerosis. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Muvalaplin?
Muvalaplin is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Atherosclerosis. According...